|
rs121913150
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
[Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of insulin receptor observed in insulin resistant diabetes].
|
1470163 |
1992 |
|
rs12696304
|
|
|
0.010 |
GeneticVariation |
BEFREE |
[CC] genotype of rs16847897 and [GG] genotype of rs12696304 together increased the risk of T2DM significantly [OR = 1.7, p = 0.004].
|
26720590 |
2015 |
|
rs16847897
|
|
|
0.010 |
GeneticVariation |
BEFREE |
[CC] genotype of rs16847897 and [GG] genotype of rs12696304 together increased the risk of T2DM significantly [OR = 1.7, p = 0.004].
|
26720590 |
2015 |
|
rs111248619
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response.
|
31324766 |
2019 |
|
rs1465146591
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response.
|
31324766 |
2019 |
|
rs386418874
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response.
|
31324766 |
2019 |
|
rs4072825
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response.
|
31324766 |
2019 |
|
rs4532315
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response.
|
31324766 |
2019 |
|
rs13266634
|
|
|
1.000 |
GeneticVariation |
BEFREE |
ZnT8 null mice have a mild phenotype with a slight decrease in glucose tolerance, whereas patients with the ZnT8 R325W polymorphism (rs13266634) have decreased proinsulin staining and susceptibility to T2DM.
|
27899481 |
2017 |
|
rs367543060
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Yet, there was no significant association of GIPR rs1800437 or GLP-1R rs367543060 with T2DM risk.
|
28744963 |
2017 |
|
rs1535500
|
|
|
0.830 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs7041847
|
|
|
0.820 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs9470794
|
|
|
0.810 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs831571
|
|
|
0.830 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs3786897
|
|
|
0.820 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs16955379
|
|
|
0.810 |
GeneticVariation |
BEFREE |
With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388).
|
31145772 |
2019 |
|
rs516946
|
|
|
0.820 |
GeneticVariation |
BEFREE |
With respect to rs516946, individuals carrying TT or CT exhibited a decreased risk of T2DM compared with those with the CC allele (adjusted P=0.040, OR=0.79; 95% CI, 0.63-0.99).
|
28912869 |
2017 |
|
rs10761600
|
|
|
0.020 |
GeneticVariation |
BEFREE |
With respect to rs10761600, AT contributed to a higher risk of T2DM compared with AA (adjusted by sex, age, and BMI, P= 0.013, OR = 1.585, 95% CI 1.101-2.282), while TT also increased the risk of presenting with T2DM compared with AA or A (adjusted by sex, age, and BMI, P= 0.004, OR = 1.632, 95% CI 1.166-2.284).
|
28469100 |
2017 |
|
rs35927125
|
|
|
0.060 |
GeneticVariation |
BEFREE |
With respect to Q62R, despite >99% power to detect an association of the previously published magnitude, Q62R was not associated with type 2 diabetes (pooled odds ratio 0.97 [95% CI 0.88-1.08], P = 0.63).
|
17130512 |
2006 |
|
rs854560
|
|
|
0.060 |
GeneticVariation |
BEFREE |
With regard to the PON1 L55M polymorphism, significant protective effects of the 55M allele on T2DM under the heterozygous (OR = 0.77, 95% CI = 0.61-0.97) and dominant (OR = 0.80, 95% CI = 0.65-0.99) genetic models were found in the European population, while no significant associations in the Asian populations under all genetic models (P > 0.05).
|
29314660 |
2018 |
|
rs25487
|
|
|
0.020 |
GeneticVariation |
BEFREE |
While Val762Ala polymorphism was associated with reduced susceptibility to DR, the Arg399Gln polymorphism contributed an elevated to risk for DR in South-Indian T2DM individuals.
|
24621175 |
2016 |
|
rs375442845
|
|
|
0.010 |
GeneticVariation |
BEFREE |
While Val762Ala polymorphism was associated with reduced susceptibility to DR, the Arg399Gln polymorphism contributed an elevated to risk for DR in South-Indian T2DM individuals.
|
24621175 |
2016 |
|
rs548450663
|
|
|
0.010 |
GeneticVariation |
BEFREE |
While Val762Ala polymorphism was associated with reduced susceptibility to DR, the Arg399Gln polymorphism contributed an elevated to risk for DR in South-Indian T2DM individuals.
|
24621175 |
2016 |
|
rs10830963
|
|
|
0.900 |
GeneticVariation |
BEFREE |
While marginal evidence of interaction between self-reported morningness-eveningness preference and rs10830963 in risk of type 2 diabetes was seen, this interaction did not persist when analysis was expanded to include all participants regardless of employment status and when accelerometer-derived sleep midpoint was used as an objective measure of morningness-eveningness preference.
|
31757795 |
2020 |
|
rs10010131
|
|
|
0.060 |
GeneticVariation |
BEFREE |
While FTO rs8050136 and rs17817449, ADAMTS9 rs4607103, and WFS1 rs10010131 were initially associated with T2DM, this was lost upon multiple testing correction.
|
24145053 |
2013 |